Overview

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of ALKS 5461 when administered daily for 4 weeks to adults with Major Depressive Disorder (MDD) and inadequate response to antidepressant therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Alkermes, Inc.